Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)Charles A. Herzog, Eberhard Ritz, Richard Asinger et al.|Kidney International|2011Cited by 925
Myocardial Fibrosis as an Early Manifestation of Hypertrophic CardiomyopathyCarolyn Y. Ho, Christine E. Seidman, Begoña López et al.|New England Journal of Medicine|2010Cited by 706
The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint dataVictor J. Dzau, Michael A. Weber, Kenneth E. Bernstein et al.|The American Journal of Cardiology|2001Cited by 260
Diltiazem Treatment for Pre-Clinical Hypertrophic Cardiomyopathy Sarcomere Mutation CarriersCarolyn Y. Ho, Christine E. Seidman, Neal K. Lakdawala et al.|JACC Heart Failure|2014Cited by 158
The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart ‘OMics’ in AGEing (HOMAGE) randomized clinical trialJohn G.F. Cleland, Theis Lange, Pierpaolo Pellicori et al.|European Heart Journal|2020Cited by 143